Global /India /Healthcare /Drug Manufacturers - General /ZYDUSLIFE
chevron_leftBack
Zydus Lifesciences Ltd. logo

Zydus Lifesciences Ltd.

ZYDUSLIFE
NSE: ZYDUSLIFE Delayed
891.90INR -2.1%
9.45 USD
As of 24 June 2026, Zydus Lifesciences Ltd. has a market cap of $9.67B USD, ranking #2264 globally and #120 in India. It ranks #168 in the Healthcare sector, and #62 in the Drug Manufacturers - General industry.
Global Rank
2264
Country Rank
120
Sector Rank
168
Industry Rank
62
Key Stats
Market Cap
$9.67BUSD
916.53B INR
Enterprise Value
$10.27BUSD
970.08B INR
Revenue (TTM)
$2.75BUSD
260.89B INR
EBITDA (TTM)
$770.78MUSD
72.78B INR
Net Income (TTM)
$521.21MUSD
49.38B INR
EBITDA Margin
28%
Profit Margin
19%
PE Ratio
18.6
Forward PE
21.4
PS Ratio
3.5
PB Ratio
3.3
EV/EBITDA
13.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Sharvil Patel open_in_new
Employees
27,917
Founded
1952
Website
zyduslife.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-2.1% -1.9% 1.6% 1.6% -9% 2.7%

News

Loading...

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
ZYDUSLIFE
Zydus Lifesciences Ltd
ISIN: INE010B01027
Shares Out.:
1.006B1 Shares Float: 249.919M2
TV:
SA:
YF:
GF:
BA:
MS:
891.90 INR
Bombay Stock Exchange
MIC: XBOM
532321 (ZYDUSLIFE)
Zydus Lifesciences Ltd
ISIN: INE010B01027
TV:
SA:
YF:
GF:
BA:
MS:
910.40 INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Zydus Lifesciences Ltd.

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Similar Companies

Industry: Drug Manufacturers - General (India)
Name
Market Cap diff.
PE
$45.04B
4.27T INR
366%
39.1
DIVISLAB
$18.31B
1.73T INR
89%
70.0
$15.11B
1.43T INR
56%
63.0
$11.69B
1.11T INR
21%
19.6
MANKIND
$9.83B
931.67B INR
1.7%
52.2
$7.17B
679.06B INR
-26%
63.8
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
8K%
38.1
JNJ
$547.28B
6K%
26.4
ABBV
$360.63B
4K%
97.4
$316.71B
256.25B CHF
3K%
19.9
AZN
$285.49B
215.59B GBP
3K%
27.6
MRK
$274.03B
3K%
15.1
chevron_leftBack